Current use of molecular profiling for indeterminate thyroid nodules.

Even though cytology remains the gold standard to assess the nature of thyroid nodules, up to 30% of the results are indeterminate (BethesdaIII and IV). In these cases, current guidelines recommend performing diagnostic surgery, which proves malignancy in only 15-30% of cases. A more precise method is needed to avoid unnecessary surgeries, surgical complications and costs in the process of diagnosing indeterminate nodules. Complementary use of molecular profiling tests seems to help in this complex scenario. We present a review of the current literature on the usefulness of molecular profiling of thyroid nodules so as to define its indications, costs and usability for clinical practice.